Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients.

Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, De Champs C.

Crit Care. 2008;12(3):R69. doi: 10.1186/cc6907. Epub 2008 May 20.

2.

TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5).

Robin F, Delmas J, Chanal C, Sirot D, Sirot J, Bonnet R.

Antimicrob Agents Chemother. 2005 Nov;49(11):4443-7.

3.

[VCA agar (bioMérieux) for selective isolation of vancomycin-resistant Enterococci (VRE) from fecal specimens].

Delmas J, Robin F, Romaszko JP, Baraduc R, Lesens O, Sirot J, Bonnet R.

Pathol Biol (Paris). 2005 Oct-Nov;53(8-9):485-9. Epub 2005 Aug 3. French.

PMID:
16084029
4.

Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability.

Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R.

J Mol Biol. 2005 Apr 29;348(2):349-62.

PMID:
15811373
5.

Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study.

De Champs C, Chanal C, Sirot D, Baraduc R, Romaszko JP, Bonnet R, Plaidy A, Boyer M, Carroy E, Gbadamassi MC, Laluque S, Oules O, Poupart MC, Villemain M, Sirot J.

J Antimicrob Chemother. 2004 Sep;54(3):634-9. Epub 2004 Jul 28.

PMID:
15282240
6.

Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum beta-lactamase CTX-M-9.

Aumeran C, Chanal C, Labia R, Sirot D, Sirot J, Bonnet R.

Antimicrob Agents Chemother. 2003 Sep;47(9):2958-61.

7.

Effect of D240G substitution in a novel ESBL CTX-M-27.

Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, De Champs C, Sirot J.

J Antimicrob Chemother. 2003 Jul;52(1):29-35. Epub 2003 May 29.

PMID:
12775683
8.

Inducible AmpC beta-lactamase of a new member Enterobacteriaceae.

Bonnet R, Chanal C, Ageron E, Sirot D, De Champs C, Grimont P, Sirot J.

Antimicrob Agents Chemother. 2002 Oct;46(10):3316-9.

9.

Prospective survey of beta-lactamases produced by ceftazidime- resistant Pseudomonas aeruginosa isolated in a French hospital in 2000.

De Champs C, Poirel L, Bonnet R, Sirot D, Chanal C, Sirot J, Nordmann P.

Antimicrob Agents Chemother. 2002 Sep;46(9):3031-4.

10.

Susceptibility of Enterobacteriaceae to beta-lactam agents and fluoroquinolones: a 3-year survey in France.

Sirot J, Nicolas-Chanoine MH, Chardon H, Avril JL, Cattoen C, Croix JC, Dabernat H, Fosse T, Ghnassia JC, Lecaillon E, Marmonier A, Roussel-Delvallez M, Soussy CJ, Trevoux A, Vandenesch F, Dib C, Moniot-Ville N, Rezvani Y.

Clin Microbiol Infect. 2002 Apr;8(4):207-13.

11.

Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis.

Bonnet R, Marchandin H, Chanal C, Sirot D, Labia R, De Champs C, Jumas-Bilak E, Sirot J.

Antimicrob Agents Chemother. 2002 Jun;46(6):2004-6.

12.

Campylobacter fetus bacteraemia in a renal graft recipient.

Heng AE, De Champs C, Souweine B, Guy L, Sirot J, Deteix P.

Nephrol Dial Transplant. 2002 Apr;17(4):689-90. No abstract available.

PMID:
11917074
13.

TEM derivative-producing Enterobacter aerogenes strains: dissemination of a prevalent clone.

Dumarche P, De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J.

Antimicrob Agents Chemother. 2002 Apr;46(4):1128-31.

14.

CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France.

Dutour C, Bonnet R, Marchandin H, Boyer M, Chanal C, Sirot D, Sirot J.

Antimicrob Agents Chemother. 2002 Feb;46(2):534-7.

15.

Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly.

Bonnet R, Dutour C, Sampaio JL, Chanal C, Sirot D, Labia R, De Champs C, Sirot J.

Antimicrob Agents Chemother. 2001 Aug;45(8):2269-75.

16.

Identification of human enterovirulent Escherichia coli strains by multiplex PCR.

Rich C, Alfidja A, Sirot J, Joly B, Forestier C.

J Clin Lab Anal. 2001;15(2):100-3.

PMID:
11291113
17.

New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates.

de Champs C, Monne C, Bonnet R, Sougakoff W, Sirot D, Chanal C, Sirot J.

Antimicrob Agents Chemother. 2001 Apr;45(4):1278-80.

18.

First isolation of a CTX-M-3-producing Enterobacter cloacae in France.

Doucet-Populaire F, Ghnassia JC, Bonnet R, Sirot J.

Antimicrob Agents Chemother. 2000 Nov;44(11):3239-40. No abstract available.

19.

[Antibiogram Committee of the French Microbiology Society. Report 2000-2001].

Soussy CJ, Carret G, Cavallo JD, Chardon H, Chidiac C, Choutet P, Courvalin P, Dabernat H, Drugeon H, Dubreuil L, Goldstein F, Jarlier V, Leclercq R, Nicolas-Chanoine MH, Philippon A, Quentin C, Rouveix B, Sirot J.

Pathol Biol (Paris). 2000 Nov;48(9):832-71. French. No abstract available.

PMID:
11141919
20.

Ventilator-associated sinusitis: microbiological results of sinus aspirates in patients on antibiotics.

Souweine B, Mom T, Traore O, Aublet-Cuvelier B, Bret L, Sirot J, Deteix P, Gilain L, Boyer L.

Anesthesiology. 2000 Nov;93(5):1255-60.

PMID:
11046214
21.

A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group.

De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J.

Antimicrob Agents Chemother. 2000 Nov;44(11):3177-9.

22.

A novel class A extended-spectrum beta-lactamase (BES-1) in Serratia marcescens isolated in Brazil.

Bonnet R, Sampaio JL, Chanal C, Sirot D, De Champs C, Viallard JL, Labia R, Sirot J.

Antimicrob Agents Chemother. 2000 Nov;44(11):3061-8.

23.

[Verotoxin-producing Escherichia coli infections: study of its prevalence in children in the Auvergne region].

Pradel N, De Champs C, Palcoux JB, Sirot J, Forestier C, Joly B, Scheutz F, Livrelli V.

Arch Pediatr. 2000 Jun;7 Suppl 3:544s-550s. French.

PMID:
10941478
24.

Role of infection control measures in limiting morbidity associated with multi-resistant organisms in critically ill patients.

Souweine B, Traore O, Aublet-Cuvelier B, Bret L, Sirot J, Laveran H, Deteix P.

J Hosp Infect. 2000 Jun;45(2):107-16.

PMID:
10860687
25.

A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil.

Bonnet R, Sampaio JL, Labia R, De Champs C, Sirot D, Chanal C, Sirot J.

Antimicrob Agents Chemother. 2000 Jul;44(7):1936-42.

26.

Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital.

Chanal C, Bonnet R, De Champs C, Sirot D, Labia R, Sirot J.

Antimicrob Agents Chemother. 2000 Jul;44(7):1930-5.

27.

Clinical relevance of Proteus mirabilis in hospital patients: a two year survey.

de Champs C, Bonnet R, Sirot D, Chanal C, Sirot J.

J Antimicrob Chemother. 2000 Apr;45(4):537-9.

PMID:
10747835
28.

Decreased susceptibility to extended-spectrum cephalosporins of a penicillin-susceptible Streptococcus pneumoniae in meningitis.

De Champs C, Constantin JM, Bonnet R, Guelon D, Goldstein F, Sirot J.

Infection. 2000 Jan-Feb;28(1):58-9.

PMID:
10697797
29.

Prevalence and characterization of Shiga toxin-producing Escherichia coli isolated from cattle, food, and children during a one-year prospective study in France.

Pradel N, Livrelli V, De Champs C, Palcoux JB, Reynaud A, Scheutz F, Sirot J, Joly B, Forestier C.

J Clin Microbiol. 2000 Mar;38(3):1023-31.

30.

Isolation of Pantoea agglomerans in two cases of septic monoarthritis after plant thorn and wood sliver injuries.

De Champs C, Le Seaux S, Dubost JJ, Boisgard S, Sauvezie B, Sirot J.

J Clin Microbiol. 2000 Jan;38(1):460-1.

31.

Dialysis and central venous catheter infections in critically ill patients: results of a prospective study.

Souweine B, Traore O, Aublet-Cuvelier B, Badrikian L, Bret L, Sirot J, Gazuy N, Laveran H, Deteix P.

Crit Care Med. 1999 Nov;27(11):2394-8.

PMID:
10579254
32.

Diversity of TEM mutants in Proteus mirabilis.

Bonnet R, De Champs C, Sirot D, Chanal C, Labia R, Sirot J.

Antimicrob Agents Chemother. 1999 Nov;43(11):2671-7.

33.

Human and animal epidemic of Yersinia enterocolitica O:9, 1989-1997, Auvergne, France.

Gourdon F, Beytout J, Reynaud A, Romaszko JP, Perre D, Theodore P, Soubelet H, Sirot J.

Emerg Infect Dis. 1999 Sep-Oct;5(5):719-21.

34.

Inhibitor-resistant OXY-2-derived beta-lactamase produced by Klebsiella oxytoca.

Sirot D, Labia R, Pouedras P, Chanal-Claris C, Cerceau C, Sirot J.

Antimicrob Agents Chemother. 1998 Sep;42(9):2184-7.

35.

Non-O157:H7 Stx2-producing Escherichia coli strains associated with sporadic cases of hemolytic-uremic syndrome in adults.

Bonnet R, Souweine B, Gauthier G, Rich C, Livrelli V, Sirot J, Joly B, Forestier C.

J Clin Microbiol. 1998 Jun;36(6):1777-80.

36.

Chromosomally encoded ampC-type beta-lactamase in a clinical isolate of Proteus mirabilis.

Bret L, Chanal-Claris C, Sirot D, Chaibi EB, Labia R, Sirot J.

Antimicrob Agents Chemother. 1998 May;42(5):1110-4.

37.

Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244.

Bret L, Chaibi EB, Chanal-Claris C, Sirot D, Labia R, Sirot J.

Antimicrob Agents Chemother. 1997 Nov;41(11):2547-9.

38.

A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.

Sirot D, Recule C, Chaibi EB, Bret L, Croize J, Chanal-Claris C, Labia R, Sirot J.

Antimicrob Agents Chemother. 1997 Jun;41(6):1322-5.

39.

[Statistical study of the SIRSCAN computerised camera].

Acar J, Bellon O, Chardon H, Charrel J, Goldstein F, Labia R, Sirot J.

Pathol Biol (Paris). 1997 May;45(5):383-8. French.

PMID:
9296089
40.

Novel extended-spectrum TEM-type beta-lactamase from an Escherichia coli isolate resistant to ceftazidime and susceptible to cephalothin.

Chanal-Claris C, Sirot D, Bret L, Chatron P, Labia R, Sirot J.

Antimicrob Agents Chemother. 1997 Mar;41(3):715-6.

41.

Enteroadherent Escherichia coli and diarrhea in children: a prospective case-control study.

Forestier C, Meyer M, Favre-Bonte S, Rich C, Malpuech G, Le Bouguenec C, Sirot J, Joly B, De Champs C.

J Clin Microbiol. 1996 Dec;34(12):2897-903.

42.

Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains.

Bret L, Chanal C, Sirot D, Labia R, Sirot J.

J Antimicrob Chemother. 1996 Aug;38(2):183-91.

PMID:
8877532
43.

Survey of prevalence of extended spectrum beta-lactamases among enterobacteriaceae.

Chanal C, Sirot D, Romaszko JP, Bret L, Sirot J.

J Antimicrob Chemother. 1996 Jul;38(1):127-32.

PMID:
8858464
44.

[Detection of pneumococci with reduced susceptibility to penicillin G using the ATB++STREP strip].

Romaszko JP, Chanal C, Sirot D, Sirot J.

Pathol Biol (Paris). 1996 May;44(5):355-7. French.

PMID:
8758475
45.

Detection of extended-spectrum plasmid-mediated beta-lactamases by disk diffusion.

Sirot J.

Clin Microbiol Infect. 1996 Feb;2 Suppl 1:S35-S39. No abstract available.

46.

Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria.

Sirot J, Courvalin P, Soussy CJ.

Clin Microbiol Infect. 1996 Feb;2 Suppl 1:S5-S10. No abstract available.

47.

First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains.

Lemozy J, Sirot D, Chanal C, Huc C, Labia R, Dabernat H, Sirot J.

Antimicrob Agents Chemother. 1995 Nov;39(11):2580-2.

48.

Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group.

Chardon H, Farzaneh S, Labia R, Jarlier V, Nicolas MH, Paul G, Poyart C, Sirot D, Sirot J.

J Antimicrob Chemother. 1995 Jul;36(1):267-9. No abstract available.

PMID:
8537279
49.

[Detection of beta-lactamases resistant to inhibitors (IRT) by the disk diffusion method].

Romaszko JP, Bret L, Henquell C, Sirot D, Chanal C, Sirot J.

Pathol Biol (Paris). 1995 Apr;43(4):306-9. French.

PMID:
7567120
50.

Supplemental Content

Support Center